Abstract
All human immunodeficiency virus type-1 (HIV-1) viruses use CD4 to enter cells. Consequently, the viral envelope CD4-binding site (CD4bs) is relatively conserved, making it a logical neutralizing antibody target. It is important to understand how CD4-binding site variation allows for escape from neutralizing antibodies. Alanine scanning mutagenesis identifies residues in antigenic sites, whereas escape mutant selection identifies viable mutants. We selected HIV-1 to escape CD4bs neutralizing mAbs b12, A12 and HJ16. Viruses that escape from A12 and b12 remained susceptible to HJ16, VRC01 and J3, whilst six different viruses that escape HJ16 remained sensitive to A12, b12 and J3. In contrast, their sensitivity to VRC01 was variable. Triple HJ16/A12/b12-resistant virus proved that HIV-1 could escape multiple broadly neutralizing monoclonal antibodies, but still retain sensitivity to VRC01 and the llama-derived J3 nanobody. This antigenic variability may reflect that occurring in circulating viruses, so studies like this can predict immunologically relevant antigenic forms of the CD4bs for inclusion in HIV-1 vaccines.
References
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C F BarbasE Norrby
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D R BurtonR A Lerner
Jan 24, 1985·Nature·L RatnerK Baumeister
Aug 1, 1983·Virology·S Z SalahuddinR C Gallo
Aug 1, 1994·Journal of Virology·P RobenD R Burton
Nov 11, 1994·Science·D R BurtonP L Nara
Mar 1, 1996·Journal of Virology·F GaoB H Hahn
Sep 1, 1997·Journal of Virology·H MoD D Ho
Aug 11, 2001·Science·E O SaphireI A Wilson
Jun 29, 2002·Science·Brian GaschenBette Korber
Jul 11, 2006·Expert Review of Vaccines·Barton F Haynes, David C Montefiori
Feb 16, 2007·Nature·Tongqing ZhouPeter D Kwong
Oct 10, 2008·Journal of Virology·Anna ForsmanRobin A Weiss
Apr 21, 2009·Journal of Molecular Biology·Laura M WalkerDennis R Burton
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Marie PanceraPeter D Kwong
Jan 26, 2010·PloS One·Davide CortiAntonio Lanzavecchia
Jul 10, 2010·Science·Tongqing ZhouPeter D Kwong
Jul 10, 2010·Science·Xueling WuJohn R Mascola
Aug 4, 2010·The Journal of Experimental Medicine·John PietzschMichel C Nussenzweig
Aug 6, 2010·The Journal of General Virology·Hanna DrejaAine McKnight
Jun 4, 2011·Retrovirology·Lachlan GrayPaul R Gorry
Jul 1, 2011·Journal of Virology·Yuxing LiJohn R Mascola
Feb 22, 2012·Journal of Virology·Emilia FalkowskaDennis R Burton
May 30, 2012·The Journal of Experimental Medicine·Laura E McCoyRobin A Weiss
Oct 30, 2012·Nature·Florian KleinMichel C Nussenzweig
Feb 13, 2013·The Journal of Experimental Medicine·Laura E McCoy, Robin A Weiss
Jul 23, 2013·PloS One·Sunita S Balla-JhagjhoorsinghGuido Vanham
Jul 24, 2013·Proceedings of the National Academy of Sciences of the United States of America·Craig S PaceDavid D Ho
Citations
Apr 16, 2016·Drug Discovery Today·Sophie SteelandClaude Libert
Oct 25, 2017·Viral Immunology·Mahmoud Mohammad YaseenMohammad Mahmoud Yaseen
Jul 22, 2020·Proceedings of the National Academy of Sciences of the United States of America·Magnus A G HoffmannPamela J Bjorkman
Jun 2, 2016·Retrovirology·Sung Yong ParkHa Youn Lee
Mar 13, 2021·Science·Daniel M AltmannRupert Beale
Jun 8, 2021·Virus Research·Yuanyuan HuZheng Wang